Application of DFNA5 / GSDME inhibitor in preparation of medicine for treating Alzheimer's disease

Through DFNA5/GSDME inhibitors, targeted knockdown or silencing the GSDME gene, the problem of limited efficacy of existing Alzheimer's treatment methods is solved, significantly improving the cognitive level and neurons of Alzheimer's model mice. Injury, which provides new potential treatments for Alzheimer's disease.

CN118949042AInactive Publication Date: 2024-11-15EAST CHINA UNIV OF SCI & TECH +1
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411401632.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-09
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing Alzheimer's treatment methods have limited efficacy and no treatments for reversible diseases. They currently rely mainly on reducing the production of beta-amyloid or promoting its clearance, but their effectiveness is not good.

Method used

Develop a DFNA5/GSDME inhibitor that reduces its expression level or inhibits its activity by targeting knockdown or silencing the GSDME gene to improve cognitive levels in Alzheimer's disease. The inhibitor includes specific shRNA or ASO sequences for GSDME expression in astrocytes or whole brain, enabling targeted gene editing through gene editing techniques.

Benefits of technology

In Alzheimer's disease model mice, it significantly improves cognitive levels, reduces neuronal damage and inflammatory response, reduces the accumulation of β-amyloid, and alleviates pathological changes in Alzheimer's disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118949042A_ABST
    Figure CN118949042A_ABST
Patent Text Reader

Abstract

The invention relates to an application of a DFNA5 / GSDME inhibitor in preparation of a medicine for treating Alzheimer's disease. The invention also provides an application of the specific DFNA5 gene knock-down system in preparation of drugs for treating Alzheimer's disease. The invention proves that the mRNA expression level of the GSDME in reactive astrocytes of a patient suffering from the Alzheimer's disease is remarkably high, and the GSMDE can be used as an effective target of the Alzheimer's disease. The invention provides application of a reagent for specifically inhibiting GSDME gene expression in astrocytes in preparation of a medicine for treating Alzheimer's disease to develop a novel treatment medicine for Alzheimer's disease, and proves that the reagent for inhibiting GSDME gene expression can be used for preparing the medicine for treating Alzheimer's disease and has a wide application prospect. The invention also provides a theoretical basis for clinical treatment of Alzheimer's disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to an application of a DFNA5 / GSDME inhibitor in the preparation of a drug for treating Alzheimer's disease. Background Art

[0002] Alzheimer's disease (AD) is a common neurodegenerative disease, characterized by memory loss, cognitive dysfunction, behavioral changes, and decreased ability to function in daily life. AD usually develops in people over the age of 65 and is the most common form of Alzheimer's disease. Pathological features include the accumulation of amyloid-β (Aβ) plaques and neurofibrillary tangles (caused by abnormal phosphorylation of tau protein) in the brain. These pathological changes lead to neuronal damage and death, ultimately causing a reduction in brain volume and severe impairment of cognitive function.

[0003] At present, the pathogenesis of Alzheimer's disease is still not fully understood. The main hypothesis is the amyloid hypothesis, which believes that the accumulation of Aβ plaques is the main cause of neuronal damage. Based on this theory, many drug research and development are committed to reducing the production of Aβ or promoting its clearance. However, clinical trial results show that the efficacy of many anti-Aβ drugs is limited. Currently approved Alzheimer's drugs mainly include cholinesterase inhibitors (such as donepezil, galantamine) and NMDA receptor antagonist memantine. Clinical studies have shown that these drugs cannot cure or reverse the disease. In addition, some emerging treatment strategies such as immunotherapy (antibody therapy), gene therapy and stem cell therapy are also being explored and developed. There is currently no treatment that can reverse the disease.

[0004] GSDME (Gasdermin E) was originally discovered as a protein that plays an important role in apoptosis and inflammation and is highly expressed in cancer cells. The present invention confirms that the mRNA expression level of GSDME is significantly high in reactive astrocytes of patients with Alzheimer's disease, and GSMDE can be used as an effective target for Alzheimer's disease. Summary of the invention

[0005] In view of the problems existing in the prior art, the present invention provides an application of a DFNA5 / GSDME inhibitor in the preparation of a drug for treating Alzheimer's disease.

[0006] In order to achieve the above objectives, the present invention provides a use of a DFNA5 / GSDME inhibitor in the preparation of a drug for treating Alzheimer's disease.

[0007] Preferably, the DFNA5 / GSDME inhibitor is a protein molecule, a nucleic acid molecule, a small molecule compound, a virus particle, or any combination of two or more thereof that inhibits or reduces the activity of GSDME or the expression level of DFNA5.

[0008] Preferably, the DFNA5 / GSDME inhibitor is a targeted gene editing system that knocks out, knocks down or silences the DFNA5 gene; preferably, the DFNA5 / GSDME inhibitor is a substance that knocks out, knocks down or silences GSDME in astrocytes or the entire brain.

[0009] Preferably, the specific DFNA5 gene knockdown system comprises a shRNA or ASO sequence that targets and knocks down the DFNA5 gene, wherein the shRNA sequence is shown in SEQ ID No. 4, and the ASO sequence is shown in SEQ ID No. 6. The DFNA5 is a human DFNA5 gene.

[0010] Preferably, the specific DFNA5 gene knockdown system comprises a shRNA or ASO sequence that targets and knocks down the DFNA5 gene, wherein the shRNA sequence is shown in SEQ ID No. 10, and the ASO sequence is shown in SEQ ID No. 11. The DFNA5 is a mouse DFNA5 gene.

[0011] The DFNA5 / GSDME inhibitors of the present invention specifically include nucleic acid inhibitors, antagonists, downregulators, blockers, blocking agents, etc., as long as they can downregulate the expression level of GSDME and inhibit the activity or function of GSDME, they can be compounds, small chemical molecules, and biological molecules. The biological molecules can be at the nucleic acid level (including DNA, RNA) or at the protein level.

[0012] In addition, the present invention includes the use of gene editing methods to inhibit or downregulate gene expression in a targeted manner through targeted gene editing. Such methods and reagents can also be applied to the present invention to prepare GSDME inhibitors.

[0013] Preferably, the DFNA5 / GSDME inhibitor is used to improve the cognitive level of Alzheimer's disease.

[0014] Preferably, the drug comprises an active ingredient and a pharmaceutically acceptable carrier, and the active ingredient is a DFNA5 / GSDME inhibitor.

[0015] The present invention also provides an application of a specific DFNA5 gene knockdown system in the preparation of a drug for treating Alzheimer's disease, wherein the specific DFNA5 gene knockdown system comprises an ASO sequence for targeting and knocking down the DFNA5 gene, wherein the ASO sequence is shown in SEQ ID No.6 or SEQ ID No.11; or, the specific DFNA5 gene knockdown system comprises an shRNA for targeting and knocking down the DFNA5 gene, wherein the shRNA sequence is shown in SEQ ID No.4 or SEQ ID No.10.

[0016] The present invention confirms that the mRNA expression level of GSDME is significantly high in reactive astrocytes of patients with Alzheimer's disease, and GSMDE can be used as an effective target for Alzheimer's disease. The present invention provides the use of a reagent that specifically inhibits the expression of GSDME gene in astrocytes or the whole brain in the preparation of a drug for treating Alzheimer's disease, so as to develop a new therapeutic drug for Alzheimer's disease. The present invention confirms that the reagent that inhibits the expression of GSDME gene can be used to prepare a drug for treating Alzheimer's disease, and the present invention also provides a theoretical basis for the clinical treatment of Alzheimer's disease. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 A graph showing the GSDME mRNA levels in non-reactive and reactive astrocytes in Alzheimer's disease.

[0018] Figure 2 a and Figure 2 b, respectively, the fluorescence intensity level and protein expression level of GSDME in HelaGSDME+ cells in the human GSDME mRNA knockdown shRNA screening experiment.

[0019] Figure 3 a and Figure 3 b, respectively, the fluorescence intensity level and protein expression level of GSDME in HelaGSDME+ cells in the human GSDME mRNA knockdown ASO screening experiment.

[0020] Figure 4 This is the genome map of AAV-GFAP-shGSDME.

[0021] Figure 5 A is a diagram showing the results of shRNA sequence screening targeting mouse GSDME; Figure 5 B is the result of AAV diffusion in the mouse cerebral cortex 6 months after AAV lateral ventricle injection; Figure 5 C is the result of immunofluorescence staining analysis of the colocalization of GFP-positive cells with astrocytes (GFAP+), microglia (Iba1+) and neurons (NeuN+); Figure 5 D is based on Figure 5 Statistical graph of C; Figure 5 E is the expression level of GSDME protein in the cerebral cortex of mice 6 months after AAV lateral ventricular injection.

[0022] Figure 6 a and Figure 6 b are the results of the Y-maze test and the novel object recognition test in the cognitive level experiment of Alzheimer's disease model mice treated with AAV-GFAP-shGSDME injection.

[0023] Figure 7 A to Figure 7 D respectively show the difference in Iba1 in the cortex of mice before and after treatment using Western blotting analysis, the relative content of Iba1 in the cortex of each group of mice using grayscale analysis, the difference in GFAP in the cortex of mice before and after treatment using Western blotting analysis, and the relative content of GFAP in the cortex of each group of mice using grayscale analysis in the experiment on the effect of AAV-GFAP-shGSDME injection on the level of cortical inflammation in Alzheimer's disease model mice.

[0024] Figure 8 A and Figure 8 B shows the difference in Aβ1-42 in the cortex of mice before and after treatment by Western blotting analysis in the experiment of the effect of AAV-GFAP-shGSDME injection on the Aβ load in the cortex of Alzheimer's disease model mice, and the relative content of Aβ1-42 in the cortex of each group of mice by grayscale analysis.

[0025] Fig. 9 A to Fig. 9 E respectively show the difference in SYP and PSD-95 in the hippocampus of mice before and after treatment in the experiment of the effect of AAV-GFAP-shGSDME injection on the survival of hippocampal neurons in Alzheimer's disease model mice, the results of Western blotting analysis, the results of grayscale analysis of the relative contents of SYP and PSD-95 in the hippocampus of mice in each group of mice, the results of Western blotting analysis of the difference in NeuN in the hippocampus of mice before and after treatment, and the results of grayscale analysis of the relative contents of NeuN in the cortex of mice in each group of mice.

[0026] Fig.10 This is the result of screening for highly efficient mouse-derived ASO-GSDME knockdown reagents.

[0027] Fig.11 This is a graph showing the diffusion of ASO-GSDME in the brain after intracerebroventricular injection.

[0028] Fig.12This is a graph showing the effect of GSDME-ASO injection therapy on the cognitive level of Alzheimer's disease model mice. DETAILED DESCRIPTION

[0029] In order to make the technical means, creative features, objectives and effects achieved by the present invention easy to understand, the present invention is further explained below with reference to specific diagrams.

[0030] In the present invention, the terms GSDME (Gasdermin E) and DFNA5 (Deafness, Autosomal Dominant 5 gene) refer to the DFNA5 gene or GSDME protein, or its homologs, or variant forms having biological activity thereof. The GSDME protein plays a key role in apoptosis and inflammatory response, preferably the human DFNA5 gene (Gene ID in NCBI: 1687).

[0031] The experimental methods described in the following examples are conventional methods unless otherwise specified; the reagents or consumables involved can be obtained through commercial channels unless otherwise specified.

[0032] like Figure 1 As shown in the results, firstly, by analyzing the snRNA-seq dataset, it was found that the mRNA expression level of GSDME in reactive astrocytes (R) of patients with Alzheimer's disease (AD) was significantly higher than that in non-reactive astrocytes (NR), that is, GSDME was upregulated in reactive astrocytes of human patients with Alzheimer's disease. This suggests that intervening in the expression of the GSDME gene may become a new approach for the treatment of Alzheimer's disease.

[0033] In order to verify this concept, the present invention uses an inhibitor that specifically targets GSDME, and constructs a specific gene knockdown system targeting GSDME, so that GSDME expression is reduced or functionally blocked in reactive astrocytes, and further proves through mouse experiments that knocking down the GSDME gene of astrocytes can improve the cognitive level of Alzheimer's model mice and alleviate Alzheimer's pathology. At the same time, the present invention uses a knockdown agent to knock down GSDME in the whole brain of mice, and also restores the cognition of Alzheimer's model mice. The present invention proves that knocking down GSDME in astrocytes or whole brain cells of mice is an effective method for treating Alzheimer's disease.

[0034] Example 1

[0035] This example is the screening and preparation of shRNA-mediated GSDME knockdown agents.

[0036] Culture of HeLa cell line constitutively expressing GSDME-GFP protein

[0037] HeLa cell line constitutively expressing human GSDME-GFP protein (the cell line was donated by Academician Shao Feng, and the original literature used is: Wang, Y., Gao, W., Shi, X., Ding, J., Liu, W., He, H., Wang, K., & Shao, F. (2017). Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of agasdermin. Nature, 547 (7661), 99–103.) was selected and grown in DMEM medium. The DMEM medium contains penicillin (100 U / ml) and streptomycin (100 mg / ml) and 10% fetal bovine serum (FBS), and the above cells are cultured at 37°C in a 5% CO2 cell culture incubator.

[0038] Screening of high-efficiency mRNA knockdown reagent shGSDME targeting human GSDME

[0039] (1) Design of shRNA targeting human GSDME. The designed shRNA sequences are shown in Table 1.

[0040] Table 1

[0041]

[0042] (2) Transfection of plasmid pLKO.1-shGE

[0043] The HeLa cells constitutively expressing GSDME-GFP were seeded in 12-well plates, and approximately 5 × 10 4 to 1×10 5 The cells were cultured at 37°C and 5% CO2 until the confluence was 60-70%. 12 hours before transfection, the culture medium in the well plate was replaced with 500 μl of 10% FBS-supplemented culture medium without double antibody.

[0044] Prepare the transfection mixture: Take a 1.5mL EP tube and add 500ng of pLKO.1-shGE plasmid to 50μL of medium (Opti-MEM) without FBS and double antibodies. In another EP tube, add 1.5μg PEI to 50μL Opti-MEM. Mix the DNA solution with the PEI solution, mix gently, and let stand for 20 minutes to form a DNA-PEI composite well plate. Slowly add the prepared DNA-PEI complex in each well to the HeLa cells in the 12-well plate and shake gently to ensure uniform distribution. Put the 12-well plate back into the cell culture incubator and incubate for 4-6 hours. Aspirate the medium without double antibodies and add 500mL of complete medium containing 10% FBS and antibiotics to continue culturing.

[0045] (3) Western Blot verification of shGSDME knockdown

[0046] Protein extraction

[0047] 48h after transfection, wash twice with PBS, collect cells into 1.5mL EP tube, add 150mL RIPA lysis buffer, stand on ice for 10 minutes, put into refrigerated centrifuge at 12000rpm, centrifuge for 10 minutes at 4℃, discard the precipitate, transfer the supernatant to the labeled EP tube, and continue to insert on ice to prevent protein degradation. Use the Biyuntian BCA protein concentration assay kit to determine the protein concentration of each group of cells, and adjust the protein concentration of each group to be consistent. Mix the protein sample with 5× loading buffer in a ratio of 4:1. The protein sample can be frozen in a -20℃ refrigerator for use or directly tested by immunoblotting (Western blot).

[0048] Western Blot Validation

[0049] Electrophoresis: Fix the SDS-PAGE electrophoresis gel in the electrophoresis tank. After spotting the samples in order, perform electrophoresis at a constant voltage of 120V for 1h. Prepare electrophoresis buffer. Electrophoresis: Take out the electrophoresis gel from the electrophoresis buffer and cut the gel according to the size of the marker protein, retaining the electrophoresis gel with two marker bands above and below 55kDa, then peel the target gel from the glass plate and place it in the electrophoresis buffer dish; cut the PVDF membrane according to the size of the protein gel. The length and width of the PVDF membrane should be slightly larger than the length and width of the gel, and soak it in methanol; cut the filter paper according to the size of the protein gel. Take out the splint used for electrophoresis, and place the filter paper, electrophoresis gel, PVDF membrane, and filter paper in the splint in sequence. Place the splint in the electrophoresis tank, pour the remaining electrophoresis buffer so that the liquid level covers the splint, and electrophoresis for 1h at a constant voltage of 100V. Blocking: Use 5% BSA, dissolved in PBST, to prepare a blocking solution. Place the transferred PVDF membrane in the blocking solution and block at room temperature for 1 hour. The blocked PVDF membrane is transferred to the primary antibody solution. The primary antibody uses GSDME antibody (abcam, ab215191) and is diluted in the blocking solution at a dilution ratio of 1:1000. The membrane is incubated with the primary antibody at 4°C overnight. Secondary antibody incubation: Remove the PVDF membrane from the primary antibody solution and rinse it three times in a plate containing TBST solution for 15 minutes each time. Select the secondary antibody according to the species source of the primary antibody, and dilute the secondary antibody in a new blocking solution according to the dilution ratio. Transfer the PVDF membrane washed 3 times to the secondary antibody solution and incubate at room temperature for 2 hours. Pour the TBST solution into the clean plate, remove the PVDF membrane from the secondary antibody solution, and rinse it three times in a plate containing TBST solution for 5 minutes each time. The PVDF membrane rinsed three times was blotted dry on filter paper, placed in the black box of the chemiluminescence instrument, and the prepared color developing solution was dropped on it to evenly cover the PVDF membrane for protein color development. The membrane was exposed and photographed to obtain GSDME protein bands before and after cutting. The same experimental method was used to obtain the internal reference band using a 1:5000 diluted GAPDH primary antibody (Hua'an Biotechnology, EM1101).

[0050] The results are as follows Figure 2 As shown in b, it can be seen that shGSDME4 (SEQ ID No. 4) can efficiently knock down the shRNA of human GSDME.

[0051] (4) Flow cytometry detection and screening of shGSDME

[0052] 48 hours after transfection, wash HeLa cells twice with PBS. Digest the cells with trypsin, collect the cells into a 1.5mL EP tube, add an appropriate amount of PBS to suspend the cells, and gently pipette to mix. Filter the cell suspension through a 100μm cell strainer to remove cell clumps. Transfer the filtered cell suspension to a flow cytometer sample tube.

[0053] Set up flow cytometer parameters:

[0054] Excitation wavelength: 488 nm for detecting GFP, 561 nm for detecting red fluorescence (shRNA plasmid).

[0055] Collection wavelengths: 530 / 30nm for GFP (green channel), 585 / 42nm for red fluorescence (red channel). Run the flow cytometer to detect the expression of GFP and red fluorescence, respectively. Analyze the data through the flow cytometry software and record the following information: Identify the single cell particle population and mark it as P1. Identify and select the red fluorescence positive cell population in the P1 cell population and mark it as P2. In the P2 cell population, measure the average fluorescence intensity of green fluorescence (GFP).

[0056] Analyze the GFP fluorescence intensity in red fluorescence positive cells, evaluate the GFP quenching caused by shRNA plasmids, and screen the shRNA sequence that efficiently knocks down GSDME. The results are shown in Figure 2 a, Verification that shGSDME4 (SEQ ID No. 4) can efficiently knock down the shRNA of human GSDME.

[0057] Example 2

[0058] This example is the screening and preparation of ASO-mediated GSDME knockdown agents.

[0059] Screening of highly efficient mRNA knockdown reagent ASO-GSDME targeting human GSDME

[0060] (1) Design of ASO sequence targeting GSDME. The designed ASO-GSDME sequence is shown in Table 2 below.

[0061] Table 2

[0062] serial number Sequence (5'-3') Chemical modification GSDME-Homo-ASO-390 ACTGGTACTTGGGTCTCTGC(SEQ ID No.5) 2'MOE;PS GSDME-Homo-ASO-575 TGAAGACTGGCTTCTACGC(SEQ ID No.6) 2'MOE;PS GSDME-Homo-ASO-649 AGATTTATTGTTCCTCGGC(SEQ ID No.7) 2'MOE;PS GSDME-Homo-ASO-1063 GAAGATATCCCATGCGCAGC(SEQ ID No.8) 2'MOE;PS GSDME-Homo-ASO-1189 AATAGGACCGCCTGGAAGAT(SEQ ID No.9) 2'MOE;PS

[0063] ASO was synthesized by Shanghai Genema Gene. The RNA on both sides was modified with methoxyethyl (MOE) 2' substitution, and the phosphate groups of the entire chain were modified with phosphorothioate (PS).

[0064] Prepare the transfection mixture: Take a 1.5mL EP tube and add 500ng ASO to 50μL Opti-MEM. In another EP tube, add 1.5μg PEI to 50μL Opti-MEM. Mix the ASO solution with the PEI solution, mix gently, and let stand for 20 minutes to form an ASO-PEI complex. Slowly add the prepared ASO-PEI complex to the HeLa cells in the 12-well plate in each well and shake gently to ensure uniform distribution. Put the 12-well plate back into the cell culture incubator and incubate for 4-6 hours. Aspirate the serum-free medium and add 1mL of complete medium containing 10% FBS and antibiotics to continue culturing.

[0065] The total cell protein extraction and Western Blot method are the same as in Example 1, and the detection results are shown in Figure 3 a, The highly efficient GSDME knockdown sequence GSDME-Homo-ASO-575 (SEQ ID No. 6) was screened.

[0066] (2) Flow cytometry detection and screening of ASO-GSDME

[0067] 48 hours after transfection, remove the culture medium in the well plate, add 500μl PBS, and repeat 2 times to wash the cells. After washing the cells, add 300μl 0.25% trypsin to each well, incubate for 3 minutes, and then add DMEM medium containing 10% fbs to each well to terminate the digestion. Gently blow the gun to suspend the adherent Hela cells and collect them in a 1.5mL EP tube. Centrifuge the collected cell suspension at 1000×g for 5 minutes, discard the supernatant, and add 500μl PBS to resuspend the cells. Repeat this washing process twice. Finally, the collected cell pellet is suspended with 200μl PBS, and the cell suspension is filtered through a 100μm cell filter to remove cell clumps. Transfer the filtered cell suspension to the flow cytometer sample tube.

[0068] Set up flow cytometer parameters:

[0069] Excitation wavelength: 488 nm was used to detect GFP.

[0070] Collection wavelength: 530 / 30nm for GFP (green channel). Run the flow cytometer to detect GFP fluorescence expression respectively. Analyze the data through the flow cytometry software and record the following information: Identify the single cell particle group and mark it as P1. Measure the average fluorescence intensity of green fluorescence (GFP) in the P1 cell group.

[0071] Analyze GFP fluorescence intensity, evaluate GFP quenching caused by ASO, and screen ASO sequences that efficiently knock down GSDME. The results are shown in Figure 3b, ASO ASO-575 (SEQ ID No. 6) was verified to be an ASO that can efficiently knock down human GSDME.

[0072] Example 3

[0073] Specific knockdown of 5xFAD astrocyte GSDME

[0074] To verify the therapeutic effect of knocking down GSDME in astrocytes on Alzheimer's disease mice, this example prepared an AAV virus that can achieve long-term specific knockdown of GSDME expression in astrocytes, and selected 5xFAD mice, a classic model mouse of Alzheimer's disease, as the treatment object.

[0075] (1) Construction of astrocyte-specific GSDME knockdown AAV

[0076] As in Example 1, mouse-derived efficient shGSDME (Ms) knockdown reagents were screened to obtain the shRNA efficient knockdown target sequence CCGGGAGCAAGTGTGAGAACCATAACTCGAGTTATGGTTCTCACACTTGCTCTTTTTT (5'-3') (SEQ ID No. 10). The constructed shRNA was loaded into the miR30 skeleton and transcribed and expressed by the astrocyte-specific promoter GFAP104 to obtain a plasmid loaded with GFAP-miR (shGSDME), and the ssAAV.PHP.eb.hGFAPS.EGFP.miR30 shRNA (GSDME).WPRE.SV40pA plasmid was constructed by Paigen Biotech, and the corresponding AAV was prepared. The plasmid map is shown in Figure 4 .

[0077] (2) Intracerebral injection of AAV virus into newborn mice

[0078] Place 5xFAD pups (P0-P3) on ice for cryoanaesthesia for 2 minutes until they completely lose reflexes. Disinfect the pup's head with 70% ethanol. Place the cryoanaesthetized pup in a slightly sideways position with the head directly under the syringe. Turn the pup's head so that the marked injection site is facing up. Use a microscope to determine and mark the injection site. With the attached microinjection needle, draw up 10 μL of AAV virus solution (1x1012 vg / mL). Insert the syringe vertically into the marked site and slowly penetrate into the lateral ventricle to a depth of approximately 1.35 mm. Begin to slowly inject the virus while monitoring the volume released from the syringe. Slowly inject 1-2 μL of virus solution at a speed of 0.2 μL / min to ensure even distribution. After the injection is completed, keep the needle in place for 1-2 minutes to avoid fluid reflux. Gradually withdraw the needle and gently press the injection site with a sterile cotton swab. Wait for the first injection site to close before injecting the other hemisphere. Remove the pup from the stereotaxic apparatus and place it on a heating pad to help it recover its body temperature. Observe the pup's recovery to ensure it is breathing and moving normally. Return the pup to its mother's nest and continue to observe for 24 hours to ensure it has recovered to normal.

[0079] As described above, ssAAV.PHP.eb.hGFAPS.EGFP.miR30shRNA(GSDME).WPRE.SV40pA and ssAAV.hGFAPS.EGFP.miR30 shRNA(NC).WPRE.SV40pA (the virus is a blank control and has no effect of knocking down the GSDME gene) were injected into the lateral ventricle of 5xFAD mice and WT mice by stereotaxic injection technology, and were recorded as shGE-5xFAD (5xFAD mouse GSDME knockdown treatment group), shNT-5xFAD (5xFAD mouse control group), shGE-WT (WT mouse GSDME knockdown control group), and shNT-WT (WT mouse control group) (n>12). The virus effect and treatment effect were verified 6 months after injection.

[0080] (3) Verification of viral expression effect by frozen sections of mouse brain

[0081] After the mice were killed by neck dislocation 6 months after injection (6 months old), the chest cavity was cut open to expose the heart to the air. At this time, the mouse heart was still beating, the right heart sinus was cut, and a 25G Baotou needle was inserted from the left ventricle of the mouse. 25-30ml PBS was slowly perfused until the outflow became transparent to ensure the purity of the tissue sample. Then, the mouse was fixed on the dissection table with its back facing up, and the mouse scalp was cut open and the skull was cut along the midline using surgical scissors and tweezers. The skull was carefully pried open to expose the brain, and the brain was carefully removed from the cranial cavity with tweezers and scissors to ensure that the brain tissue was not damaged. The entire brain removed was immediately placed in a culture dish filled with cold saline (PBS) to keep it moist. Then, the brain was cut in half along the central axis of the brain with dissecting scissors. The left hemibrain of the mouse obtained in the above steps was immersed in a 15ml centrifuge tube filled with 10ml 4% PFA configured with PBS to fix the brain tissue. After 24 hours, the liquid in the centrifuge tube was replaced with 10%, 20% and 30% sucrose solution prepared in PBS for dehydration. The dehydration time for each step was 12-24 hours, until the brain sank to the bottom of the 30% sucrose solution, indicating that the dehydration was complete. After dehydration, the brain was removed, the excess liquid on the surface was slightly dried, and then the brain was placed in the OCT embedding medium to ensure that the brain was completely immersed in OCT. The embedded brain was quickly placed in a -80°C refrigerator and frozen. After the OCT was completely solidified, it was transferred to a freezing microtome (-20°C). In the freezing microtome, a small amount of OCT was used to fix the mouse brain on the sample stage, and the settings of the microtome were adjusted to a slice thickness of 30μm. The brain tissue was cut step by step, and three brain slices were arranged on a poly-lysine slide and stored at -20°C.

[0082] Immunofluorescence staining of frozen sections: Take out the frozen sections of mouse brain obtained above, place the sections in a 60℃ oven, and perform heat repair for 10 seconds. Gently wash the sections with PBS 3 times, 5 minutes each time, to remove OCT embedding agent and other possible contaminants. Use a tissue pen to draw a circle around the tissue to circle the entire tissue, and then add 0.5% triton solution and incubate at room temperature for 30 minutes to complete the section permeabilization. After the permeabilization is completed, the triton solution is aspirated, 5% BSA is added, and incubated at room temperature for 1 hour to complete the section blocking. After this step is completed, the blocking solution is aspirated, and the primary antibody is diluted with 0.5% BSA at a ratio of 1:100. The primary antibody is diluted with the blocking solution, the mouse anti-GFAP (Cell Signaling, GA5) antibody is diluted at a ratio of 1:200, the rabbit anti-iba1 (Cell Signaling, E404W) antibody is diluted at a ratio of 1:200, and the rabbit anti-NeuN (abcam, ab177487) antibody is diluted at a ratio of 1:200. The diluted primary antibody was added to the slices and incubated overnight at 4°C. The next day, the slices were washed with PB solution 3 times for 10 minutes each time to remove the unbound primary antibody. The secondary antibody was diluted with 0.5% BSA, and the secondary antibody (anti-rabbit Alexa Fluor 647 was diluted at a ratio of 1:100, and anti-mouse Alexa Fluor594 was diluted at a ratio of 1:100) was incubated at room temperature in the dark for 2 hours. The choice of fluorescent markers should match the excitation and emission wavelengths of the microscope detection equipment. After the secondary antibody incubation is completed, the slices are washed 3 times with PBS for 10 minutes each time. After washing, the slices are slightly dry, and a fluorescence quenching sealing agent (yeasen, 36308ES20) containing DAPI (4',6-diamidino-2-phenylindole) dye is added, and the coverslip is covered and gently pressed to avoid bubbles. The sealing is completed.

[0083] The frozen sections were photographed using a Leica sp8 inverted laser confocal microscope, with the excitation light source being Wil.

[0084] The results of cryosection immunofluorescence validation are shown in Figure 5 B, 5C, and 5D, the injected AAV successfully spread in the brain, and eGFP driven by the astrocyte-specific promoter was specifically expressed in astrocytes throughout the brain.

[0085] (4) Western blot verification of GSDME knockdown in mouse brain astrocytes

[0086] Total protein extraction from tissues:

[0087] Total protein extraction of mouse cortex and hippocampus: The right hemisphere of the mouse obtained above was placed on ice, and the hippocampus and cortex were peeled off. The protein extraction was carried out on ice throughout the process, and all centrifugation steps were carried out at 4°C. The RIPA lysis buffer (yeasen) was taken out from -20°C in advance and melted, and PMSF was added a few minutes before use to make the final concentration reach 1mM. The hippocampus and cortex were placed in 100μl PBS containing 1mM PMSF, cut into pieces, and ground into homogenate with a grinding rod. Then, 100μl RIPA lysis buffer (containing 1mM PMSF) was added to the hippocampus homogenate, and 500μl RIPA lysis buffer (containing 1mMPMSF) was added to the cortex homogenate. Let it stand on ice for 10 minutes, and vortex it every 2 minutes. After the homogenate is fully lysed, centrifuge it at 10000g for 3-5 minutes, and collect the supernatant, which is the extracted total protein solution. The total protein solution was divided into two parts. One part was added with 5x protein loading buffer and boiled in boiling water for 10 minutes. The other part was divided into 20μl or 50μl and placed in a new EP tube. Both were stored at -80℃ for subsequent analysis. Through the above steps, high-quality protein samples were obtained for further research and analysis.

[0088] The obtained mouse cerebral cortex protein samples were subjected to Western blot detection (the specific method is the same as in Example 1), the primary antibody was diluted with blocking, and the rabbit anti-GSDME (abcam, ab215191) antibody was diluted at a ratio of 1:1000. The results are as follows Figure 5 As shown in E, injection treatment successfully downregulated the GSDME content in astrocytes in the cerebral cortex.

[0089] Example 4

[0090] Specific knockdown of GSDME in 5xFAD astrocytes rescues cognitive degeneration in mice.

[0091] (1) AAV-GFAP-shGSDME improves cognitive levels in Alzheimer's disease mice.

[0092] In order to detect the cognitive level of mice, the mice were subjected to Y-maze test and novel object recognition test.

[0093] Y-maze test method: A homemade Y-maze consists of three arms of equal length (50cmx18cmx35cm), with an angle of 120 degrees between each two arms, and a movable partition in the center. The arms and bottom of the maze are painted black. The ends of the maze arms are marked with patterns of different shapes (triangle, circle, star). The mouse is placed at the end of any arm of the Y-maze and allowed to explore freely for 8 minutes. The camera system records the behavioral changes of the animal for 8 minutes. The video data is analyzed by the Noldus system. The Y-maze evaluation calculation method is as follows: ① The total number of entries: the number of times the animal enters the maze arm (the rat's four feet enter the arm once as the standard); ② An alternation: enter all three arms of the Y-maze once in sequence. ③ The maximum number of alternations: the total number of entries-2. Spontaneous alternation behavior score = total number of alternations / maximum number of alternations*100%.

[0094] Novel object recognition test method: Place the mice in the open field for 5 minutes to adapt. 24 hours later, place two old batteries in the open field cage and let the mice explore freely for 10 minutes. 12 hours later, place two identical objects (consistent with the above) in the open field cage and let the mice explore freely for 10 minutes. 6 hours later, replace one of the two objects with a new object and let the mice explore freely again for 10 minutes. Calculate the preference index (PI) of the mice for the contact time and contact number of the new object.

[0095] The calculation formula for the novel object preference ratio is:

[0096]

[0097] T new : How long experimental animals spend exploring novel objects.

[0098] T old : Time of old objects in experimental animals

[0099]

[0100] N new : How long experimental animals spend exploring novel objects.

[0101] N old : Time of old objects in experimental animals.

[0102] The results of behavioral experiments are as follows Figure 6 a and Figure 6As shown in b, the results showed that the cognitive ability of 5xFAD mice was significantly reduced, and knocking down GSDME in astrocytes throughout the mouse brain could restore the mice's working memory and cognitive level.

[0103] Example 5

[0104] AAV-GFAP-shGSDME treatment alleviates neuroinflammation and neuronal and synaptic loss in Alzheimer's mice.

[0105] (1) Astrocyte-specific GSDME knockdown therapy reduces the level of glial cell activation in the cerebral cortex

[0106] The method for extracting total protein from cortical tissue was the same as in Example 3. The obtained mouse cerebral cortex protein sample was subjected to Western blot detection (the specific method was the same as in Example 1). The primary antibody was diluted with blocking agent, the dilution ratio of mouse anti-GFAP (Cell Signaling, GA5) antibody was 1:1000, the dilution ratio of antibody was 1:2000, and the dilution ratio of rabbit anti-iba1 (Cell Signaling, E404W) antibody was 1:1000.

[0107] like Figure 7 A and Figure 7 As shown in B, astrocyte-specific GSDME knockdown treatment downregulated the content of iba1, a biomarker of activated microglia. Figure 7 C and Figure 7 As shown in D, the content of GFAP, a biomarker of activated astrocytes, was downregulated.

[0108] (2) Astrocyte-specific GSDME knockdown therapy reduces brain Aβ load

[0109] The method for extracting total protein from cortical tissue was the same as in Example 3. The obtained mouse cerebral cortex protein samples were subjected to Western blot detection (the specific method was the same as in Example 1). The primary antibody was diluted with blocking agent, and mouse anti-Aβ 1-42 (abcam, AB180956) The antibody dilution ratio was 1:1000.

[0110] The results are as follows Figure 8 As shown in A and 8B, astrocyte-specific GSDME knockdown treatment downregulated the toxic form of Aβ in the cerebral cortex 1-42 The content.

[0111] (3) Astrocyte-specific GSDME knockdown therapy reduces hippocampal neuronal and synaptic loss

[0112] The method for extracting total hippocampal protein was referred to Example 3, and the obtained mouse brain hippocampal protein sample was subjected to Western blot detection (the specific method is the same as Example 1), and the primary antibody was diluted with blocking solution, the rabbit anti-NeuN (abcam, ab177487) antibody was diluted at a ratio of 1:2000, the rabbit anti-synaptophysin (proteintech, 17785-1-ap) antibody was diluted at a ratio of 1:1000, and the mouse anti-PSD-95 (santa, sc-71934) antibody was diluted at a ratio of 1:1000.

[0113] like Fig. 9 A. Fig. 9 B and Fig. 9 As shown in C, astrocyte-specific GSDME knockdown treatment upregulated the levels of synaptic biomarkers SYP and PSD-95. Fig. 9 D and Fig. 9 As shown in E, the level of neuronal biomarker NeuN was upregulated.

[0114] Example 6

[0115] Whole-brain knockdown of astrocyte GSDME improves cognitive function in 5xFAD mice

[0116] As a small nucleic acid drug, ASO does not have good cell targeting and is usually used to knock down the expression of target proteins in the whole brain during treatment. Therefore, this example tests the therapeutic effect of ASO-mediated whole-brain cell GSDME knockdown on Alzheimer's disease model mice 5xFAD mice.

[0117] (1) Screening of whole-brain mouse GSDME knockdown reagents

[0118] As in Example 2, mouse-derived efficient ASO-GSDME knockdown reagents were screened to obtain the ASO efficient knockdown target sequence AGAAATAACATGGAGTTTGC (5'-3') (SEQ ID No. 11). The ASO was synthesized by Shanghai Jima Gene, the RNA on both sides was modified by methoxyethyl (MOE) 2' substitution, and the phosphate group of the whole chain was modified by phosphorothioate (PS). The knockdown efficiency was detected by Western blot. Fig.10 .

[0119] (2) Intracerebroventricular injection of ASO-GSDEM-Ms into 2-month-old 5xFAD mice

[0120] 2-month-old 5xFAD mice were anesthetized by intraperitoneal injection of 1% sodium pentobarbital, with an injection volume of 80 mg / 100 g (mouse body weight). After 5 to 10 minutes, the anesthetic took effect, and the mouse was anesthetized. The hair on the head of the mouse was shaved with a shaver, and the mouse was fixed on a stereotaxic instrument. The skin of the mouse head was cut with a scalpel, and the connective tissue on the surface of the tibia was removed to expose the anterior and posterior bregma. The Bregma (anterior bregma) point was used as the reference point (zero point) of the three-dimensional coordinate system, and the coordinates (X=1.00 mm, Y=0.80 mm, Z=1.5 mm) were used as the injection site. The injection volume was 5 μl, and the total amount of ASO injected was 20 μg / g (mouse body weight).

[0121] As described above, ASO-GSDME-Ms and ASO-NC (the ASO is a blank control without knocking down the GSDME gene) were injected into the lateral ventricles of 2-month-old 5xFAD mice and WT mice by stereotaxic injection technology, respectively, and recorded as ASO-GE-5xFAD (5xFAD mouse GSDME knockdown treatment group), ASO-NC-5xFAD (5xFAD mouse control group), ASO-GE-WT (WT mouse GSDME knockdown control group), and ASO-NC-WT (WT mouse control group) (n>12). The therapeutic effect was verified 2 months after injection.

[0122] The injection effect was verified using the same cryosection technique as in Example 3. The injection effect of ASO was as follows: Fig.11 As shown, intracerebroventricular injection of ASO successfully enabled the efficient knockdown ASO to spread to cells throughout the brain.

[0123] (3) ASO-GSDME-Ms improves cognitive performance in Alzheimer's disease mice.

[0124] In order to detect the cognitive level of each group of mice, each group of mice was subjected to a Y-maze test. The specific experimental steps are shown in Example 5. The behavioral experimental results are shown in Fig.12 As shown, the results showed that the cognitive ability of 4-month-old 5xFAD mice was significantly reduced, and knocking down GSDME in astrocytes throughout the mouse brain could restore the working memory ability of the mice.

[0125] In this specification, the present invention has been described with reference to specific embodiments thereof. However, it is apparent that various modifications and variations may be made without departing from the spirit and scope of the present invention. Therefore, the specification and drawings should be regarded as illustrative rather than restrictive.

Claims

1. Use of a DFNA5 / GSDME inhibitor in the preparation of a drug for treating Alzheimer's disease.

2. The use according to claim 1, characterized in that: The DFNA5 / GSDME inhibitor is a protein molecule, a nucleic acid molecule, a small molecule compound, a virus particle, or any combination of two or more of the foregoing, which inhibits or reduces the activity of GSDME or the expression level of DFNA5.

3. The use according to claim 1, characterized in that: The DFNA5 / GSDME inhibitor is a substance that knocks out, knocks down or silences the DFNA5 gene; or, the DFNA5 / GSDME inhibitor is a substance that knocks out, knocks down or silences GSDME in astrocytes or the whole brain.

4. The use according to claim 3, characterized in that: The specific DFNA5 gene knockdown system includes a shRNA or ASO sequence that targets and knocks down the DFNA5 gene. The shRNA sequence is shown in SEQ ID No.4, and the ASO sequence is shown in SEQ ID No.

6.

5. The use according to claim 4, characterized in that: The DFNA5 is a human DFNA5 gene.

6. The use according to claim 3, characterized in that: The specific DFNA5 gene knockdown system includes a shRNA or ASO sequence that targets and knocks down the DFNA5 gene. The shRNA sequence is shown in SEQ ID No.10, and the ASO sequence is shown in SEQ ID No.

11.

7. The use according to claim 6, characterized in that: The DFNA5 is a mouse DFNA5 gene.

8. The use according to claim 1, characterized in that: The DFNA5 / GSDME inhibitor is used to improve the cognitive level of Alzheimer's disease.

9. The use according to claim 1, characterized in that: The medicine comprises an active ingredient and a pharmaceutically acceptable carrier, and the active ingredient is a DFNA5 / GSDME inhibitor.

10. Use of a specific DFNA5 gene knockdown system in the preparation of a drug for treating Alzheimer's disease, characterized in that: The specific DFNA5 gene knockdown system includes an ASO sequence for targeted knockdown of the DFNA5 gene, and the ASO sequence is shown as SEQ ID No.6 or SEQ ID No.11; or, the specific DFNA5 gene knockdown system includes an shRNA for targeted knockdown of the DFNA5 gene, and the shRNA sequence is shown as SEQ ID No.4 or SEQ ID No.10.

Citation Information

Cited By

  • Application of DFNA5 / GSDME inhibitor in preparation of medicine for treating Alzheimer's disease

    CN121818925A

  • Application of DFNA5 / gsdme inhibitor in preparing drug for treating alzheimer's disease

    WO2026077485A1